BioCardia (BCDA)
0.38
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 4 BioCardia, Inc. For: Apr 19 Filed by: Altman Peter
April 19, 2024 5:39 PM - SEC Filing
Form DEF 14A BioCardia, Inc. For: May 20
April 15, 2024 5:17 PM - SEC Filing
Form SC 13D/A BioCardia, Inc. Filed by: Frost Gamma Investments Trust
April 5, 2024 4:14 PM - SEC Filing
Form PRE 14A BioCardia, Inc. For: May 20
April 4, 2024 5:03 PM - SEC Filing
Form EFFECT BioCardia, Inc.
April 2, 2024 6:05 AM - SEC Filing
Form 4 BioCardia, Inc. For: Mar 28 Filed by: Altman Peter
March 28, 2024 7:34 PM - SEC Filing
Form S-8 BioCardia, Inc.
March 27, 2024 4:10 PM - SEC Filing
Form 8-K BioCardia, Inc. For: Mar 27
March 27, 2024 4:08 PM - SEC Filing
Form 10-K BioCardia, Inc. For: Dec 31
March 27, 2024 4:06 PM - SEC Filing
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
March 27, 2024 4:00 PM - Globe NewsWire
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
March 20, 2024 7:00 AM - Globe NewsWire
BioCardia (BCDA) and StemCardia Announce Biotherapeutic Delivery Partnership
March 13, 2024 7:02 AM - StreetInsider
Form 8-K BioCardia, Inc. For: Mar 13
March 13, 2024 7:00 AM - SEC Filing
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
March 13, 2024 7:00 AM - Globe NewsWire
Form 8-K BioCardia, Inc. For: Mar 06
March 12, 2024 4:34 PM - SEC Filing
Form 8-K BioCardia, Inc. For: Mar 12
March 12, 2024 7:00 AM - SEC Filing
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
March 12, 2024 7:00 AM - Globe NewsWire
Form 8-K BioCardia, Inc. For: Mar 04
March 4, 2024 8:01 AM - SEC Filing
BioCardia (BCDA) Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial
March 4, 2024 8:01 AM - StreetInsider
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
March 4, 2024 8:00 AM - Globe NewsWire
Form SC 13D/A BioCardia, Inc. Filed by: Frost Gamma Investments Trust
February 27, 2024 4:55 PM - SEC Filing
Form 4 BioCardia, Inc. For: Feb 13 Filed by: Altman Peter
February 15, 2024 7:01 AM - SEC Filing
Form SC 13G/A BioCardia, Inc. Filed by: SATTERFIELD THOMAS A JR
February 14, 2024 5:07 PM - SEC Filing
BioCardia (BCDA) Announces 3.02M Share Offering by Selling Stockholders
February 14, 2024 4:38 PM - StreetInsider
Form S-3 BioCardia, Inc.
February 14, 2024 4:35 PM - SEC Filing
Form 8-K BioCardia, Inc. For: Feb 09
February 9, 2024 9:59 AM - SEC Filing
Form 8-K BioCardia, Inc. For: Feb 08
February 8, 2024 7:04 AM - SEC Filing
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
February 8, 2024 7:00 AM - Globe NewsWire
Form SC 13D/A BioCardia, Inc. Filed by: Frost Gamma Investments Trust
February 6, 2024 4:28 PM - SEC Filing
Form SC 13G/A BioCardia, Inc. Filed by: Francis Capital Management, LLC
February 2, 2024 2:06 PM - SEC Filing
Form 8-K BioCardia, Inc. For: Jan 31
January 31, 2024 7:00 AM - SEC Filing
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
January 31, 2024 7:00 AM - Globe NewsWire
Full Article List
